CNSY Nasdaq · formerly
Plus Therapeutics
Plus Therapeutics is now Cerenome

Diagnostics,
therapeutics and data
as one system.

How the company describes its CNS oncology platform. Name changed Aug 3, 2026.

11,000+ CNSide tests since 2020,
per the company
CNSide · Diagnostics

A spinal fluid test
for CNS cancer,
in clinical use.

A laboratory-developed test. Performed at more than 120 U.S. cancer institutions, per the company.

32 patients treated at the
Phase 2 dose
REYOBIQ · Investigational

Phase 2 enrollment
complete in recurrent
glioblastoma.

Investigational and not FDA-approved. Topline data expected mid‑2027.

$1.55M Q3 gross billings,
unaudited, per company
CNSide · Commercial

Payer coverage
reaching ~164M
covered lives.

222 tests billed in Q3. Contracted commercial and Medicare Advantage lives, per the company.

INVESTOR RELATIONS · NASDAQ: CNSY
Opened in a new tab: enter your email there.

Opens the email-alert form on ir.cerenome.com in a new tab. This ad does not collect or send your email.

Forward-looking statements, including trial timing and results and CNSide coverage, reimbursement and billing, involve risks; actual results may differ materially. REYOBIQ is investigational and not FDA-approved. Billings are unaudited gross billings. See SEC filings for risk factors.